Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based in NJ, United States.
| Revenue (Most Recent Fiscal Year) | $44.54M |
| Net Income (Most Recent Fiscal Year) | $-83.78M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 12.48 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -144.63% |
| Net Margin (Trailing 12 Months) | -144.63% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -52.40% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.19 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.74 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 2.42 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.45 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.18 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.78 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.65 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 125.51M |
| Free Float | 116.97M |
| Market Capitalization | $675.25M |
| Average Volume (Last 20 Days) | 3.90M |
| Beta (Past 60 Months) | 1.48 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.81% |
| Percentage Held By Institutions (Latest 13F Reports) | 32.45% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |